IN8bio Inc (INAB) Stock Price

1.49 ▼ -0.10 (-6.29%)
Open: 1.43 Vol: 0 Day's range: 1.41 - 1.49 May 15, 15:59 EDT
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
INAB Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 1.49▲ 1.47▲ 1.47▲ 1.58▼ 1.50▼
MA10 1.48▲ 1.54▼ 1.55▼ 1.59▼ 1.56▼
MA20 1.57▼ 1.57▼ 1.58▼ 1.54▼ 1.81▼
MA50 1.59▼ 1.56▼ 1.56▼ 1.58▼ 2.00▼
MA100 1.57▼ 1.53▼ 1.51▼ 1.80▼ 1.18▲
MA200 1.50▼ 1.48▲ 1.52▼ 1.90▼ 1.38▲
  5 mins 30 mins Hourly Daily Weekly
MACD -0.009▼ -0.016▼ -0.018▼ 0.004▲ -0.034▼
RSI 39.234▼ 40.043▼ 40.223▼ 44.636▼ 44.834▼
STOCH 37.959     21.429     25.595     61.880     20.877    
WILL %R -67.347     -67.347     -67.347     -68.000     -77.500▼
CCI -30.815     -58.904     -78.940     -143.573▼ -46.115    
Latest Filters Detected On INAB
RSI $INAB RSI(14) Crossed Below 50 Set Alert
MA $INAB Price Crossed Below MA(50) Set Alert
MA $INAB Price Crossed Below MA(26) Set Alert
MA $INAB Price Crossed Below MA(13) Set Alert
▼ GAP $INAB Open Gap Down %5 Set Alert
▼ GAP $INAB Open Gap Down %3 Set Alert
▼ GAP $INAB Open Gap Down %2 Set Alert
IN8bio Inc News
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Saturday, April 04, 2026 09:23 PM
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE)-- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative γδ T cell therapies for cancer and autoimmune ...
IN8bio (INAB) Q2 Loss Narrows 77%
Thursday, August 07, 2025 09:26 AM
Net loss (GAAP) narrowed significantly in Q2 2025 due to reduced operational costs, though no revenue was recorded. Clinical trial results for INB-200 in glioblastoma showed a median progression-free ...
Kill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potential
Wednesday, April 10, 2024 03:38 AM
Tuesday, IN8bio Inc (NASDAQ:INAB) revealed new preclinical data from its non-signaling gamma-delta T cell-based Chimeric Antigen Receptor-T cell (nsCAR) platform, known as INB-300. The data showed ...
INAB historical stock data
date open high low close volume
15/05/26 1.43 1.49 1.41 1.49 128,713
14/05/26 1.65 1.66 1.59 1.59 22,769
13/05/26 1.62 1.62 1.59 1.59 14,785
12/05/26 1.6269 1.635 1.59 1.60 32,099
11/05/26 1.61 1.64 1.5916 1.625 67,118
08/05/26 1.66 1.66 1.552 1.58 42,515
07/05/26 1.60 1.63 1.56 1.60 45,068
06/05/26 1.63 1.63 1.50 1.58 74,710
05/05/26 1.60 1.65 1.60 1.62 36,817
04/05/26 1.49 1.61 1.49 1.61 76,634
Quote Details
52wk Low:0.101
52wk High:4.17
Vol:0
Avg Vol(3m):1.2M
1Y Chng:+1,104.53%
1M Chng:+5.67%
Add to Watch List
More Information
Index US Composite
Market Cap. 15.85M